Synthesis of Novel Aliphatic N-sulfonylamidino Thymine Derivatives by Cu(I)-catalyzed Three-component Coupling Reaction by Krstulović, Luka et al.
 
† This article belongs to the Special Issue devoted to the 85th anniversary of Croatica Chemica Acta. 
* Author to whom correspondence should be addressed. (E-mail: bzinic@irb.hr) 
CROATICA CHEMICA ACTA 
CCACAA, ISSN 0011-1643, e-ISSN 1334-417X 
Croat. Chem. Acta 85 (4) (2012) 525–534.  
http://dx.doi.org/10.5562/cca2198 
Original Scientific Article 
Synthesis of Novel Aliphatic N-sulfonylamidino Thymine Derivatives by 
Cu(I)-catalyzed Three-component Coupling Reaction†  
Luka Krstulović,a Hamit Ismaili,b Miroslav Bajić,a Aleksandar Višnjevac,c 
Ljubica Glavaš-Obrovac,d,e and Biserka Žinić f,*  
aFaculty of Veterinary Medicine, University of Zagreb, Heinzelova 55, HR-10000 Zagreb, Croatia 
bFaculty of Mathematics and Natural Sciences, University of Pristina, Agim Ramadani n.n. 10000, Pristina, Kosovo  
cDivision of Physical Chemistry, Ruđer Bošković Institute, Bijenička cesta 54, HR-10000 Zagreb, Croatia  
dDepartment of Clinical Chemistry and Biochemistry, School of Medicine, J. J. Strossmayer University of Osijek, 
Huttlerova 4, HR-31000 Osijek, Croatia  
eClinical Hospital Centre Osijek, Clinical Institute of Nuclear Medicine and Radiation Protection, 
Huttlerova 4, HR-31000 Osijek, Croatia  
fDivision of Organic Chemistry and Biochemistry, Ruđer Bošković Institute, Bijenička cesta 54, HR-10000 Zagreb, Croatia 
RECEIVED OCTOBER 12, 2012; REVISED NOVEMBER 20, 2012; ACCEPTED NOVEMBER 20, 2012  
 
Abstract. A series of new aliphatic N-sulfonylamidino thymine derivatives containing nucleobase, 
N-sulfonyl and amidine pharmacophores in the structure were synthesized by Cu(I)-catalyzed three-
component coupling of 1-propargyl thymine, benzenesulfonyl azides and amines or ammonium salts. Pre-
liminary in vitro antitumor screening (human cervix adenocarcinoma -HeLa and leukemia cells - Jurkat) 
revealed promising activities of N,N-diethyl- (2) and N-4-cyanobenzyl- (6) derivatives of 4-acetamido- 
benzenesulfonyl amidine. (doi: 10.5562/cca2198) 
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INTRODUCTION 
Search for new and more efficient anticancer drugs still 
presents one of major challenges of modern medicine 
and medicinal chemistry.1,2 Due to the vast biological 
diversity of cancer, including more than 100 different 
types, there is a constant urge to discover of new mole-
cules possessing more specific anticancer activity and 
lower toxicity.3 Sulfonamides are known as extremely 
useful pharmaceutical compounds exhibiting a wide 
range of biological activities.4–7 We have recently 
shown that N-sulfonylpyrimidine derivatives of type I 
(Figure 1) possess strong antitumor activity under  
in vitro and in vivo conditions.8–11 In comparison with  
5-FU (5-fluorouracil), some of the N-sulfonylpyrimidine 
derivatives showed up to 10 times stronger growth in-
hibitory effects on a number of tested tumor cells while 
the effects on normal human fibroblasts were much less 
pronounced.12 These types of nucleic base sulfonamides 
were found to inhibit DNA, RNA and protein synthesis 
and induce apoptosis in human tumor cells.12,13 In vivo 
experiments showed that some N-sulfonylcytosine deri-
vatives exhibited strong antitumor activity against mouse 
mammary carcinoma.9,14 To further explore the biologi-
cal potential of this type of molecules, their structure 
was modified by combining them with another potent 
anticancer pharmacophore - that of amidine. The 
amidine group is present in many compounds capable of 
interacting with a wide range of biological targets, re-
sulting in anti-degenerative, anticancer and antimicrobi-
al activities.15–18 Here, we report on the synthesis of a 
series of novel aliphatic thymine derivatives II (Figure 1) 
containing N-sulfonylamidino fragment attached to the 
Figure 1. N-sulfonylpyrimidine I and N-sulfonylamidino
thymine II derivatives.  
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N1 position of thymine by ethylene spacer using the 
Cu(I)-catalyzed three-component coupling reaction of 
1-propargyl thymine, selected benzenesulfonyl azides 
and amines or ammonium salts. 
In this way, a series of potentially biologically  
active N-sulfonylamidino thymine derivatives II, re-
presenting a combination of pyrimidne nucleobase,  
N-sulfonyl group and amidine group pharmacophores, 
was prepared in moderate to good yields. Structures of 
N-sulfonylamidino thymines were approved by spectro-
scopic methods and X-ray crystallography. In prelimi-
nary in vitro screening, some of the prepared type II 
compounds showed promising anticancer activity 
against two selected human tumor cell lines. The results 
presented illustrate the versatility and potential of Cu(I) 
catalyzed three-component alkyne, sulfonyl azide, 
amine coupling for the preparation of N-sulfonyl-
amidino nucleobase derivatives using propargylated 
nucleobase as the terminal alkyne component. The de-
scribed synthetic approach also appears suitable for the 
preparation of libraries of N-sulfonylamidino 
nucleobase derivatives representing a new structural 
type of molecules with potential anticancer activity. 
 
EXPERIMENTAL 
General 
Solvents were distilled from appropriate drying agents 
shortly before use. TLC was carried out on DC-
plastikfolien Kieselgel 60 F254 and preparative thick 
layer (2 mm) chromatography was done on Merck 60 
F254. Melting points were determined on a Kofler hot-
stage apparatus and were uncorrected. UV Spectra 
[λmax /nm, log ε /dm3 mol–1 cm–1] were taken on a Philips 
PU8700 UV/VIS spectrophotometer. IR spectra 
[max /cm–1] were obtained for KBr pellets on a Perkin-
Elmer 297 spectrophotometer. 1H and 13C NMR spectra 
were recorded in DMSO-d6 on Bruker AV 300 and 600 
MHz spectrometers using TMS or DMSO-d6 as the 
internal standard. Elemental analyses were performed 
by the Applied Laboratory Research Department at 
INA, d.d. Research and Development Sector, Central 
Analytical Laboratory.  
 
5-Methyl-1-(prop-2-ynyl)pyrimidine-2,4(1H,3H)-dione 
(1-propargyl thymine) 
To an acetonitrile suspension of thymine (2 g, 15.86 
mmol), N,O-bis(trimethylsilyl)acetamide (BSA) (8.08 
mL, 31.72 mmol) was added under argon and stirred at 
80 °C for 30 min. The solution was cooled to room 
temperature and propargyl bromide (3.77 g, 31.72 mmol) 
was added. The reaction mixture was kept in dark for 14 
days, acetonitrile was partly evaporated and then 5.0 mL 
of MeOH was added, inducing crystallization of 1-pro-
pargyl thymine (1.63 g, 63 %) m.p. = 152–154 °C (Ref. 
34) m.p. = 157–158 °C); Rf = 0.77 (CH2Cl2/MeOH 9:1); 
1H NMR (300 MHz, DMSO-d6) δ /ppm: 11.32 (s, 1H, 
NH-3), 7.54 (s, 1H, H-6), 4.45 (d, 2H, J = 2.4 Hz,  
CH2-1'), 3.35 (t, 1H, J = 2.5 Hz, CH-3'), 1.75 (s, 3H, 
CH3-5); 13C NMR (150 MHz, DMSO-d6) δ /ppm: 
166.36 (s, C-4), 150.31 (s, C-2), 140.07 (d, C-6), 109.36 
(s, C-5), 78.60 (s, C-2'), 75.55 (s, CH-3'), 36.26 (t, CH2-
1'), 11.84 (q, CH3-5); IR (KBr) ν /cm–1: 3406 (w), 3254 
(s), 2126 (m), 1707 (s), 1691 (s), 1652 (s), 1473 (m), 
1424 (s), 1356 (m), 1245 (m), 1136 (m), 933 (m). 
 
General Procedures for the Preparation of N-Sulfonyl 
Amidines 
Method A 
To a stirred mixture of alkyne (1 mmol), sulfonyl azide 
(1.2 mmol), and CuI (0.1 mmol) in dry THF (2 mL), 
amine nucleophile (1.2 mmol) was slowly added. The 
reaction mixture was stirred for 24 h at room tempera-
ture and diluted with a small amount of cold methanol. 
The product was collected by filtration and dissolved in 
hot MeOH. The crude amidine product was filtered 
through a short Al2O3 column, evaporated and the ana-
lytically pure product was obtained by recrystallization 
using methanol. 
 
Method B 
To a stirred mixture of alkyne (1 mmol), CuI (0.1 
mmol) and amine/ammonium salt (1 mmol) in dry 
CH2Cl2 (2 mL), triethylamine (1.5 mmol) was slowly 
added and the colour of the suspension turned light 
yellow. After that, sulfonyl azide (1 mmol) was added. 
The reaction mixture was stirred for 24 h at room tem-
perature and diluted with a small amount of cold metha-
nol. The product was collected by filtration and dis-
solved in hot MeOH. The crude amidine product was 
filtered through a short Al2O3 column, evaporated and 
the analytically pure product was obtained by recrystal-
lization using methanol. 
 
Method C 
To a stirred mixture of alkyne (1 mmol), sulfonyl azide 
(1.2 mmol), and CuI (0.1 mmol) in THF (2 mL), amine 
nucleophile (2.4 mmol) was slowly added. The reaction 
mixture was stirred for 24 h (4 h in the case of com-
pound 13) at room temperature, dissolved in MeOH and 
filtered through a short Celite column. The filtrate was 
partially evaporated and the residue was filtered off. 
The crude product was dissolved in a water solution of 
NaHCO3 (w = 5 %) and the water solution was washed 
with dichloromethane and ethyl acetate. The water 
phase was neutralized with 5 % CH3COOH and partial-
ly evaporated. The product was collected by filtration 
and recrystallized from methanol. 
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N1,N1-diisopropyl-N2-(4-acetoamidobenzene-1-sulfonyl)- 
3 - (5 - methyl - 2,4 - dioxo - 3,4 - dihydropyrimidin-1(2H) - yl) 
propanamidine (1) Method A. White solid (78 %); m.p. 
= 226 °C; Rf = 0,78 (CH2Cl2/MeOH 9:1); UV (MeOH): 
λmax /nm: 264 (log ε /dm3 mol–1 cm–1: 4,7); 1H NMR 
(600 MHz, DMSO-d6) δ /ppm: 11.35 (brs, 1H, NH-3'), 
10.24 (s, 1H, NH-Ac), 7.72 (s, 4H, Ph), 7.26 (s, 1H,  
H-6'), 4.33-4.26 (m, 1H, CH-(CH3)2), 3.91 (t, 2H, J3,2 = 
7.8 Hz, CH2-3), 3.66 (m, 1H, CH-(CH3)2), 3.19 (t, 2H, 
J2,3 = 7.4 Hz, CH2-2), 2.07 (s, 3H, CO-CH3), 1.77  
(s, 3H, CH3-5'), 1.19 (pt, 12H, J = 6.5 Hz, CH-(CH3)2); 
13C NMR (150 MHz, DMSO-d6) δ /ppm: 168.86 (s,  
CO-CH3), 164.27 (s, C-4'), 161.66 (s, C-1), 150.93  
(s, C-2'), 141.90 (s, Ph), 140.6 (d, C-6'), 138.11 (s, Ph), 
126.51 (d, Ph), 118.32 (d, Ph), 109.11 (s, C-5'),  
50.20 (d, CH-(CH3)2), 47.34 (d, CH-(CH3)2), 45.08  
(t, CH2-3), 31.21 (t, CH2-2), 24.09 (q, CO-CH3),  
20.08 (q, CH-(CH3)2), 19.58 (q, CH-(CH3)2), 11.98 (q,  
CH3-5'); IR (KBr) ν /cm–1: 3323 (m), 3182 (m), 3123 
(m), 3006 (m), 2982 (m), 2838 (m), 1707 (s), 1685 (s), 
1540 (s), 1375 (m), 1269 (m), 1085 (m). Anal. Calcd. 
mass fractions of elements, w /%, for C22H31N5O5S × 
0.5 H2O (Mr = 486.58): C, 54.30; H, 6.63; N, 14.39;  
S, 6.59. Found: C, 54.14; H, 6.50; N, 14.43; S, 6.42. 
 
N1,N1 - diethyl - N2 - (4 - acetoamidobenzene - 1 - sulfonyl) - 3 -
(5 - methyl - 2,4 – dioxo - 3,4 - dihydropyrimidin -1(2H) - yl)-
propanamidine (2) Method A. White solid (64 %); m.p. 
= 230–232 °C; Rf = 0.55 (CH2Cl2/MeOH 9:1); UV 
(MeOH): λmax /nm: 264 (log ε /dm3 mol–1 cm–1: 4,7); 1H 
NMR (300 MHz, DMSO-d6) δ /ppm: 11.35 (brs, 1H, 
NH-3), 10.25 (s, 1H, NH-Ac), 7.75 (d, 2H, J = 8.9 Hz, 
Ph), 7.70 (d, 2H, J = 8.9 Hz, Ph), 7.24 (s, 1H, H-6'), 
3.94 (t, 2H, J3,2 = 7.2 Hz, CH2-3), 3.48 (q, 2H, J = 6.6 
Hz, CH2-CH3), 3.38 (q, 2H, J = 6.6 Hz, CH2-CH3), 3.13 
(t, 2H, J2',1' = 7.3 Hz, CH2-2), 2.07 (s, 3H, CO-CH3), 
1.76 (s, 3H, CH3-5'), 1.15 (t, 3H, J = 7.1 Hz, CH2-CH3), 
0.99 (t, 3H, J = 7.0 Hz, CH2-CH3); 13C NMR (150 MHz, 
DMSO-d6) δ /ppm: 168.86 (s, CO-CH3), 164.23 (s,  
C-4'), 162.89 (s, C-1), 150.91 (s, C-2'), 142.00 (s, Ph), 
140.55 (d, C-6'), 138.15 (s, Ph), 126.58 (d, Ph), 118.39 
(d, Ph), 109.14 (s, C-5'), 45.27 (t, CH2-3), 43.09 (t,  
CH2-CH3), 42.96 (t, CH2-CH3), 29.75 (t, CH2-2),  
24.09 (q, CO-CH3), 13.88 (q, CH2-CH3), 11.98 (q,  
CH2-CH3) 11.77 (q, CH3-5'); IR (KBr) ν /cm–1: 3290 
(m), 3124 (w), 3124 (w), 3035 (w), 2980 (w), 2840 (w), 
1714 (m), 1663 (s), 1554 (s), 1255 (m), 1140 (m), 832 
(m). Anal. Calcd. mass fractions of elements, w /%, for 
C20H27N5O5S (Mr = 449.52): C, 53.44; H, 6.05; N, 15.58; 
S, 7.13. Found: C, 53.38; H, 5.65; N, 15.79; S, 6.96.  
N1 - isopropyl - N2 - (4 - acetoamidobenzene - 1 - sulfonyl) - 3 - 
(5 - methyl - 2,4 - dioxo - 3,4 - dihydropyrimidin - 1(2H) -yl)-
propanamidine (3) Method A. White solid (54 %); m.p. 
= 216–217 °C; Rf = 0.50 (CH2Cl2/MeOH 9:1); UV 
(MeOH): λmax /nm: 263 (log ε /dm3 mol–1 cm–1: 4.6); 1H 
NMR (300 MHz, DMSO-d6) δ /ppm: 11.24 (brs, 1H, 
NH-3'), 10.28 (s, 1H, NH-Ac), 8.67 (brs, 1H, NH-CH), 
7.73 (d, 2H, J = 9,3 Hz, Ph), 7.72 (d, 2H, J = 9.3 Hz, 
Ph), 7.19 (d, 1H, H-6'), 4.0 (t, 2H, J3,2 = 6.3 Hz, CH2-3), 
3.87 (m, 1H, CH-(CH3)2), 2.88 (t, 2H, J2,3 = 6.1 Hz, 
CH2-2), 2.07 (s, 3H, CO-CH3), 1.71 (s, 3H, CH3-5'), 
1.00 (d, 6H, J = 6.8 Hz, CH-(CH3)2); 13C NMR (150 
MHz, DMSO-d6) δ /ppm: 168.85 (s, CO-CH3), 164.32 
(s, C-4'), 163.62 (s, C-1), 150.69 (s, C-2'), 141.97 (s, 
Ph), 141.03 (d, C-6'), 138.15 (s, Ph), 126,65 (d, Ph), 
118.80 (d, Ph), 108.33 (s, C-5'), 45.45 (t, CH2-3), 43.14 
(d, CH-(CH3)2), 33.22 (t, CH2-2), 24.08 (q, CO-CH3), 
21.09 (q, CH-(CH3)2), 12.00 (q, CH3-5'); IR (KBr) 
ν /cm–1: 3309 (m), 3124 (w), 3055 (w), 2983 (w), 1711 
(s), 1675 (s), 1554 (s), 1384 (m), 1321 (m), 1250 (m), 
1141 (m), 1090 (m). Anal. Calcd. mass fractions of 
elements, w /%, for C19H25N5O5S × H2O (Mr = 453.51): 
C, 50.32; H, 6.00; N, 15.44; S, 7.07. Found: C, 50.16; 
H, 5.61; N, 15.35; S, 6.94. 
 
N1-cyclopentyl-N2-(4-acetoamidobenzene-1-sulfonyl)-3-
(5 - methyl - 2,4 - dioxo - 3,4 - dihydropyrimidin - 1(2H)-yl)-
propanamidine (4) Method A. White solid (58 %); m.p. 
= 155–157 °C; Rf = 0,77 (CH2Cl2/MeOH 9:1); UV 
(MeOH): λmax /nm: 264 (log ε /dm3 mol–1 cm–1: 4.5); 1H 
NMR (300 MHz, DMSO-d6) δ /ppm: 11.24 (brs, 1H, 
NH-3'), 10.24 (s, 1H, NH-Ac), 8.70 (d, 1H, J = 6.6 Hz, 
NH-cyclopentyl), 7.75 (d, 2H, J = 9.0 Hz, Ph), 7.69 (d, 
2H, J = 9.0 Hz, Ph), 7.16 (s, 1H, H-6'), 3.98 (t, 2H, J1',2' 
= 5.8 Hz, CH2-3), 3.98 (m, 1H, CH-cyclopentyl), 2.88 
(t, 2H, J2',1' = 5.9 Hz, CH2-2), 2.07 (s, 3H, CO-CH3), 
1.70 (s, 3H, CH3-5'), 1.29-1.81 (m, 8H, CH2-cyclo-
pentyl); 13C NMR (150 MHz, DMSO-d6) δ /ppm: 
168.83 (s, CO-CH3), 164.30 (s, C-1), 164.08 (s, C-4'), 
150.68 (s, C-2'), 141.94 (s, Ph), 140.93 (d, C-6'), 138.16 
(s, Ph), 126.66 (d, Ph), 118.32 (d, Ph), 108.33 (s, C-5'), 
52.87 (d, CH-cyclopentyl) 45.44 (t, CH2-3), 33.11 (t, 
CH2-2), 31.35 (t, CH2-cyclopentyl), 24.09 (q, CO-CH3), 
23.49 (t, CH2-cyclopentyl),12.00 (q, CH3-5'); IR (KBr) 
ν /cm–1: 3327 (s), 3012 (m), 2959 (m), 2836 (w), 1696 
(s), 1672 (s), 1568 (s), 1521 (s), 1316 (m), 1255 (s), 
1148 (s), 1102 (m). Anal. Calcd. mass fractions of ele-
ments, w /%, for C21H27N5O5S (Mr = 461.53): C, 54.65; 
H, 5.90; N, 15.17; S, 6.95. Found: C, 54.36; H, 5.82; N, 
15.08; S, 6.66. 
 
N1 - (quinolin - 6 - yl) - N2 - (4- acetoamidobenzene - 1 - sulfonyl) - 
3 - (5 - methyl-2,4 - dioxo - 3,4 - dihydropyrimidin-1(2H)-yl)- 
propanamidine (5) Method A. Skin-colored solid (54 %); 
m.p. = 219–221 °C; Rf = 0.40 (CH2Cl2/MeOH 9:1); UV 
(MeOH): λmax /nm: 263 (log ε /dm3 mol–1 cm–1: 4.5); 1H 
NMR (300 MHz, DMSO-d6) δ /ppm: 11.26 (brs, 1H, 
NH-3'), 10.68 (brs, 1H, NH-quinolinyl), 10.29 (s, 1H, 
NH-Ac), 8.84 (d, 1H, J = 3.7 Hz, Ph), 8.11 (d, 2H, J = 
13.6 Hz, Ph), 7.96 (d, 1H, J = 8.9 Hz, Ph) 7.85 (d, 2H, J 
= 8.8 Hz, Ph), 7.76 (d, 2H, J = 8.8 Hz, Ph), 7.70 (m, 1H, 
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Ph), 7.50 (m, 1H, Ph), 7.37 (s, 1H, H-6'), 4.17 (t, 2H, 
J1',2' = 5.6 Hz, CH2-3), 3.20 (t, 2H, J2',1' = 5.5 Hz, CH2-
2), 2.08 (s, 3H, CO-CH3), 1.68 (s, 3H, CH3-5'); 13C 
NMR (150 MHz, DMSO-d6) δ /ppm: 168.93 (s, CO-
CH3), 164.34 (s, C-4'), 163.19 (s, C-1), 150.92 (s, C-2'), 
150.07 (d, Ph), 145.32 (s, Ph), 142.43 (s, Ph), 141.04 (d, 
C-6'), 137.08 (s, Ph), 135.61 (d, Ph), 129.27 (d, Ph), 
127.68 (s, Ph) 126.95 (d, Ph), 125.22 (d, Ph), 121,97 (d, 
Ph), 119.13 (d, Ph), 118.45 (d, Ph), 108.64 (s, C-5') 
45.62 (t, CH2-3), 34.15 (t, CH2-2), 24.12 (q, CO-CH3), 
11.98 (q, CH3-5'); IR (KBr) ν /cm–1: 3486 (m), 3292 
(m), 3066 (m), 2956 (m), 2770 (m), 1670 (s), 1546 (s), 
1281 (s), 1149 (s), 1090 (s). Anal. Calcd. mass fractions 
of elements, w /%, for C25H24N6O5S × 1.5 H2O (Mr = 
547.58): C, 54.83; H, 4.97; N, 15.34; S, 5.85. Found: C, 
55.21; H, 4.94; N, 15.18; S, 5.68.  
 
N1- (4 - cyanobenzyl) - N2 - (4 - acetoamidobenzene - 1 -sulfonyl) - 
3 - (5 - methyl - 2,4 - dioxo - 3,4 - dihydropyrimidin-1(2H) - 
yl)propanamidine (6) Method B. White solid (45 %); 
m.p. = 142–145 °C; Rf = 0.54 (CH2Cl2/MeOH 9:1); UV 
(MeOH): λmax /nm: 237 (log ε /dm3 mol–1 cm–1: 4.7); 
λmax /nm: 264 (log ε/ dm-3 mol-1cm-1: 4,7) 1H NMR (300 
MHz, DMSO-d6) δ /ppm: 11.25 (brs, 1H, NH-3'), 10.25 
(s, 1H, NH-Ac), 9.34 (brs, 1H, NH-CH2), 7.72 (d, 2H, J 
= 8.0 Hz, Ph), 7.66 (d, 2H, J = 8.7 Hz, Ph), 7.60 (d, 2H, 
J = 8.7 Hz, Ph) 7.36 (d, 2H, J = 8.0 Hz, Ph), 7.21 (s, 1H, 
H-6'), 4.37 (d, 2H, J = 5.4 Hz, NH-CH2), 4.01 (t, 2H, 
J2,3 = 6.0 Hz, CH2-3), 3.00 (t, 2H, J3,2 = 6.3 Hz, CH2-2), 
2.07 (s, 3H, CO-CH3), 1.68 (s, 3H, CH3-5'); 13C NMR 
(150 MHz, DMSO-d6) δ /ppm: 168.92 (s, CO-CH3), 
165.18 (s, C-4'), 164.35 (s, C-1), 150.78 (s, C-2'), 
143.24 (d, Ph), 142.11 (s, Ph), 140.90 (d, C-6'), 137.64 
(s, Ph), 132.21 (s, Ph), 128.57 (d, Ph), 126.68 (d, Ph), 
118.77 (s, CN), 118.33 (d, Ph), 109.89 (s, Ph), 108.67 
(s, C-5'), 45.55 (t, NH-CH2), 44.57 (t, CH2-3), 33.04 (t, 
CH2-2), 24.12 (q, CO-CH3), 12.00 (q, CH3-5'); IR (KBr) 
ν /cm–1: 3333 (s), 3110 (m), 3059 (m), 2922 (m), 2860 
(m), 2230 (w), 1675 (s), 1562 (s), 1246 (m), 1145 (m), 
1091 (m). Anal. Calcd. mass fractions of elements, 
w /%, for C20H24N6O5S × H2O (Mr = 526.56): C, 54.74; 
H, 4.98; N, 15.95; S, 6.09. Found: C, 55.12; H, 4.71; N, 
15.88; S, 5.95. 
 
N - (4 - acetoamidobenzene - 1 - sulfonyl) - 3 - (5 - methyl - 2,4 -
dioxo - 3,4 - dihydropyrimidin - 1(2H) - yl)propanamidine (7) 
Method B. White solid (56 %); m.p. = 219 °C; Rf = 0,47 
(CH2Cl2/MeOH 9:1); UV (MeOH): λmax /nm: 264 
(logε/dm3 mol–1 cm–1: 4.5); 1H NMR (300 MHz, DMSO-
d6) δ /ppm: 11.22 (s, 1H, NH-3'), 10.28 (s, 1H, NH-Ac), 
8.67 (s, 1H, NH2), 7.91 (s, 1H, NH2), 7.77 (d, 2H, J = 
8.8 Hz, Ph), 7.71 (d, 2H, J = 8,8 Hz, Ph), 7.18 (s, 1H, H-
6'), 3.80 (t, 2H, J3,2 = 6,1 Hz, CH2-3), 2.57 (t, 2H, J2,3 = 
6.3 Hz, CH2-2), 2.08 (s, 3H, CO-CH3), 1.62 (s, 3H, 
CH3-5'); 13C NMR (150 MHz, DMSO-d6) δ /ppm: 
168.89 (s, CO-CH3), 165.89 (s, C-4'), 164.21 (s, C-1), 
150.67 (s, C-2'), 142.55 (s, Ph), 141.59 (d, C-6'), 136.16 
(s, Ph), 127.12 (d, Ph), 118.32 (d, Ph), 108.01 (s, C-5'), 
44.92 (t, CH2-3), 34.81 (t, CH2-2), 24.10 (q, CO-CH3), 
11.89 (q, CH3-5’); IR (KBr) ν /cm–1: 3366 (s), 3197 (s), 
3096 (m), 3050 (m), 2960 (m), 1669 (s), 1573 (s), 1255 
(s), 1128 (s), 1074 (s). Anal. Calcd. mass fractions of ele-
ments, w /%, for C16H19N5O5S (Mr = 393.42): C, 48.85; 
H, 4.87; N, 17.80. Found: C, 48.87; H, 4.90; N, 17.66. 
 
N1,N1 - diisopropyl - N2 - (4 - methylbenzene - 1 - sulfonyl) - 3- 
(5 - methyl - 2,4 - dioxo - 3,4 - dihydropyrimidin - 1(2H) - yl) -
propanamidine (8) Method A. White solid (54 %); m.p. 
= 243–245 °C; Rf = 0.78 (CH2Cl2/MeOH 9:1); UV 
(MeOH): λmax /nm: 252 (log ε /dm3 mol–1 cm–1: 4.3); 1H 
NMR (300 MHz, DMSO-d6) δ /ppm: 11.35 (brs, 1H, 
NH-3'), 7.68 (d, 2H, J = 8.0 Hz, Ph), 7.35 (d, 2H, J = 
8.0 Hz, Ph), 7.26 (s, 1H, H-6'), 4.27 (m, 1H, CH-
(CH3)2), 3.92 (t, 2H, J = 7.3 Hz, CH2-3), 3.66 (m, 1H, 
CH-(CH3)2), 3.19 (t, 2H, J = 7.2 Hz, CH2-2), 2.36 (s, 
3H, CH3-Ts), 1.76 (s, 3H, CH3-5'), 1.19 (pt, 12H, J = 
5.8 Hz, CH-(CH3)2); 13C NMR (75 MHz, DMSO-d6) 
δ /ppm: 164.27 (s, C-4'), 161.81 (s, C-1), 150.93 (s, C-
2'), 141.5 (s, Ph), 141.4 (s, Ph), 140.59 (s, C-6'), 129.24 
(d, Ph), 125.48 (d, Ph), 109.11 (s, C-5'), 50.24 (d, CH-
(CH3)2), 47.35 (d, CH-(CH3)2), 45.08 (t, CH2-3), 31.30 
(t, CH2-2), 20.91 (q, CH3-Ts), 20.09 (q, CH-(CH3)2), 
19.57 (q, CH-(CH3)2),11.99 (q, CH3-5'); IR (KBr) ν/cm–1: 
3157 (w), 3042 (w), 2979 (w), 2933 (w), 1686 (s), 1553 
(s), 1463 (m), 1344 (m), 1266 (s), 1136 (m), 1085 (m). 
Anal. Calcd. mass fractions of elements, w /%, for 
C21H30N6O5S (Mr = 434.55): C, 58.04; H, 6.96; N, 
12.89. Found: C, 57.73; H, 6.64; N, 12.85.  
N1- cyclopentyl - N2 - (4 - methylbenzene - 1 - sulfonyl) - 3 - (5 - 
methyl - 2,4 - dioxo - 3,4 - dihydropyrimidin - 1(2H) -yl)pro-
panamidine (9) Method A. White solid (45 %); m.p. = 
216–219 °C ; Rf = 0.77 (CH2Cl2/MeOH 20:1); UV 
(MeOH): λmax /nm: 212 and 241 (log ε /dm3 mol–1 cm–1: 
3.9 and 3.9), 1H NMR (300 MHz, DMSO-d6) δ /ppm: 
11.21 (s, 1H, NH-3'), 8.69 (d, 1H, J = 6.4 Hz, NH-
cyclopentyl), 7.70 (d, 2H, J = 8.5 Hz, Ph), 7.33 (d, 2H, J 
= 8.0 Hz, Ph), 7.16 (s, 1H, H-6'), 3.99 (t, 2H, J = 6.4 Hz, 
CH2-3), 3.99 (m, 1H, CH-cyclopentyl), 2.90 (t, 2H, J = 
6.1 Hz, CH2-2), 2.36 (s, 3H, CH3-Ts), 1.74 (m, 2H, 
CH2-cyclopentyl), 1.71 (s, 3H, CH3-5'), 1.51-1.39 (m, 
6H, CH2-cyclopentyl); 13C NMR (150 MHz, DMSO-d6) 
δ /ppm: 164.28 (s, C-4'), 164.20 (s, C-1), 150.66 (s, C-
2'), 141.53 (s, Ph), 141.46 (s, Ph), 140.93 (d, H-6'), 
126.20 (d, Ph), 125.01 (d, Ph), 108.33 (s, C-5'), 52.89 
(d, CH-cyclopentyl) 45.45 (t, CH2-3), 33.13 (t, CH2-2), 
31.34 (t, CH2-cyclopentyl), 23.49 (t, CH2-cyclopentyl), 
20.89 (q, CH3-Ts), 12.00 (q, CH3-5'); IR (KBr) ν /cm–1: 
3323 (s), 3142 (w), 3021 (w), 2960 (w), 2833 (w), 1692 
(s), 1674 (s), 1559 (s), 1429 (m), 1339 (m), 1262 (s), 
1149 (s), 1090 (m), 1047 (m) 717 (m), 701 (m), 683 
(m), 600 (w). Anal. Calcd. mass fractions of elements, 
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w /%, for C20H26N4O4S (Mr = 418.51): C, 57.46; H, 
6.26; N, 13.39; S, 7.66. Found: C, 57.22; H, 6.24; N, 
13.45; S, 7.58. 
 
N1 - (4 - cyanobenzyl) - N2 - (4 - methylbenzene - 1 - sulfonyl) -
3-(5 - methyl - 2,4 - dioxo - 3,4 - dihydropyrimidin - 1(2H) - yl) -
propanamidine (10) Method B. White solid (30 %); m.p. 
= 180–183 °C; Rf = 0.45 (CH2Cl2/MeOH 20:1); UV 
(MeOH): λmax /nm: 230 (log ε /dm3 mol–1 cm–1: 4.3); 1H 
NMR (300 MHz, DMSO-d6) δ /ppm: 11.24 (s, 1H, NH-
3'), 9.36 (brs, 1H, NH-CH2), 7.73 (d, 2H, J = 7.7 Hz, 
Ph), 7.56 (d, 2H, J = 7.7 Hz, Ph), 7.37 (d, 2H, J = 7.7 
Hz, Ph), 7.28 (d, 2H, J = 7.7 Hz, Ph), 7.22 (s, 1H, H-6'), 
4.37 (d, 2H, NH-CH2), 4.02 (t, 2H, J3,2 = 6.4 Hz,  
CH2-3), 3.03 (t, 2H, J3,2 = 6.4 Hz, CH2-2), 2.36 (s, 3H, 
CH3-Ts), 1.68 (s, 3H, CH3-5'); 13C NMR (150 MHz, 
DMSO-d6) δ /ppm: 165.25 (s, C-4'), 164.29 (s, C-1), 
150.73 (s, C-2'), 143.24 (s, Ph), 141.69 (s, Ph), 140.95 
(d, C-6), 140.82 (s, Ph), 132.19 (d, Ph), 129.13 (d, Ph), 
128.48 (d, Ph), 125,57 (d, Ph), 118.76 (s, CN), 109.85 
(s, Ph), 108.62 (s, C-5') 45.51 (t, NH-CH2), 44.55 (t, 
CH2-3), 33.01 (t, CH2-2), 20.89 (q, CH3-Ts), 11.99 (q, 
CH3-5'); IR (KBr) ν /cm–1: 3326 (m), 3210 (w), 3097 
(w), 2228 (w), 1692 (s), 1674 (s), 1651 (s), 1256 (m), 
1139 (m), 1097 (m). Anal. Calcd. mass fractions of 
elements, w /%, for C23H23N5O4S (Mr = 465.52): C, 
59.34; H, 4.98; N, 15.04; S, 6.89. Found: C, 59.25; H, 
5.14; N, 14.65; S, 6.65. 
 
N - (4 - methylbenzene - 1 - sulfonyl) - 3 - (5 - methyl - 2,4 - dioxo - 3,4 - 
dihydropyrimidin - 1(2H) -yl)propanamidine (11) Method B. 
White solid (39 %); m.p. = 205–207 °C; Rf = 0.33 
(CH2Cl2/MeOH 20:1); UV (MeOH): λmax /nm: 236 and 
268 (log ε /dm3 mol–1 cm–1: 3.4 and 3.7); 1H NMR (300 
MHz, DMSO-d6) δ /ppm: 11.20 (s, 1H, NH-3'), 8.68 
(brs, 1H, NH2), 7.94 (s, 1H, NH2), 7.72 (d, 2H, J = 8.5 
Hz, Ph), 7.33 (d, 2H, J = 8.1 Hz, Ph), 7.18 (d, 1H, H-6'), 
3.73 (t, 2H, J = 6.6 Hz, CH2-3), 2.60 (t, 2H, J = 6.4 Hz, 
CH2-2), 2.36 (s, 3H, CH3-Ts), 1.61 (s, 3H, CH3-5'); 13C 
NMR (150 MHz, DMSO-d6) δ /ppm: 166.01 (s, C-4'), 
164.19 (s, C-1), 150.67 (s, C-2'), 142.29 (s, Ph), 141.5 
(d, C-6), 139.59 (s, Ph), 129.27 (d, Ph), 126.02 (d, Ph), 
108.0 (s, C-5'), 44.82 (t, CH2-3), 34.80 (t, CH2-2) 20.95 
(q, CH3-Ts), 11.88 (q, CH3-5') ; IR (KBr) ν /cm–1: 3403 
(m), 3314 (m), 3217 (m), 2992 (m), 2832 (m), 1697 (s), 
1657 (s), 1553 (m), 1463 (m), 1279 (s), 1144 (s), 1086 
(m). Anal. Calcd. mass fractions of elements, w /%, for 
C15H18N4O4S (Mr = 350.38): C, 51.41; H, 5.17; N, 15.99 
S, 9.15. Found: C, 51.72; H, 5.15; N, 16.26; S, 9.28. 
 
N1,N1 - diisopropyl - N2 - (4 - carboxybenzenev- 1 - sulfonyl) -
3-(5 - methyl - 2,4 - dioxo - 3,4 - dihydropyrimidin - 1(2H) -
yl)propanamidine (12) Method C. White solid (43 %); 
m.p. = 246–249 °C; Rf = 0.42 (CH2Cl2/MeOH 9:1); UV 
(MeOH): λmax /nm: 222 and 258 (log ε /dm3 mol–1 cm–1: 
4.5 and 4.6); 1H NMR (300 MHz, DMSO-d6) δ /ppm: 
13.35 (brs, 1H, COOH), 11.34 (s, 1H, NH-3'), 8.09 (d, 
2H, J = 8.6 Hz, Ph), 7.91 (d, 2H, J = 8.5 Hz, Ph), 7.28 
(s, 1H, H-6'), 4.30 (m, 1H, CH-(CH3)2), 3.94 (t, 2H, J3,2 
= 6.9 Hz, CH2-3), 3.69 (m, 1H, CH-(CH3)2), 3.22 (t, 2H, 
J2,3 = 7.4 Hz, CH2-2), 1.76 (s, 3H, CH3-5'), 1.19 (pt, 
12H, J = 5.6 Hz, CH-(CH3)2); 13C NMR (75 MHz, 
DMSO-d6) δ /ppm: 166.33 (s, COOH) 164.26 (s, C-4'), 
162.10 (s, C-1), 150.94 (s, C-2'), 147.52 (s, Ph), 140.63 
(d, C-6'), 133.29 (s, Ph), 129.86 (d, Ph), 125.75 (d, Ph), 
109.11 (s, C-5'), 50.46 (d, CH-(CH3)2), 47.48 (d, CH-
(CH3)2), 45.09 (t, CH2-3), 31.53 (t, CH2-2), 19.99 (q, 
CH-(CH3)2), 19.53 (q, CH-(CH3)2), 11.97 (q, CH3-5'); 
IR (KBr) ν /cm–1: 3097 (w), 3049 (w), 3014 (w), 2974 
(w), 2933 (w), 1718 (s), 1689 (s), 1542 (s), 1452 (m), 
1365 (m), 1269 (s), 1083 (m). Anal. Calcd. mass frac-
tions of elements, w /%, for C21H28N4O6S x 0.25 H2O 
(Mr = 469.04): C, 53.26; H, 6.17; N, 11.83; S, 6.77. 
Found: C, 53.50; H, 6.49; N, 11.56; S, 6.95. 
 
N1 - isopropyl - N2 - (4 - carboxybenzene - 1 - sulfonyl) - 3 - (5 -
methyl - 2,4 - dioxo - 3,4 - dihydropyrimidin - 1(2H) - yl)pro-
panamidine (13) Method C. White solid (43 %); m.p. = 
245–248 °C; Rf = 0.22 (CH2Cl2/MeOH 9:1); UV 
(MeOH): λmax /nm: 245 (log ε /dm3 mol–1 cm–1: 4.4), 1H 
NMR (300 MHz, DMSO-d6) δ /ppm: 11.22 (brs, 1H, 
NH-3'), 8.81 (d, 1H, J = 7.4 Hz, NH-CH), 8.01 (d, 2H, J 
= 8.4 Hz, Ph), 7.82 (d, 2H, J = 8.1 Hz, Ph), 7.21 (d,1H, 
J = 1.2 Hz, H-6), 4.00 (t, 2H, J3,2 = 6.3 Hz, CH2-3), 3.88 
(brs, 1H, CH-(CH3)2), 2.91 (t, 2H, J2,3 = 6.3 Hz, CH2-2), 
1,71 (s, 3H, CH3-5'), 1.01 (d, 12H, J = 6.6 Hz, CH-
(CH3)2); 13C-NMR (150 MHz, DMSO-d6) δ /ppm: 
167.07 (s, COOH), 164.25 (s, C-4'), 163.86 (s, C-1), 
150.65 (s, C-2'), 145.72 (s, Ph), 140.95 (d, C-6'), 129.44 
(d, Ph), 125.18 (d, Ph), 108.33 (s, C-5'), 45.41 (t, CH2-
3), 43.23 (d, CH-(CH3)2), 33.29 (t, CH2-2), 21.01 (q, 
CH-(CH3)2), 11.91 (q, CH3-5'); IR (KBr) ν /cm–1: 3317 
(m), 3060 (w), 2975 (w), 2927 (w), 2821 (w), 1697 (s), 
1556 (s), 1467 (m), 1334 (m), 1253 (m), 1147 (m), 1126 
(m), 1093 (m), 1039 (m). Anal. Calcd. mass fractions of 
elements, w /%, for C18H22N4O6S × H2O (Mr = 440.47): 
C, 49.08; H, 5.49; N, 12.71; S, 7.27. Found: C, 48.74; 
H, 5.26; N, 12.24; S, 7.46. 
 
N1-cyclopentyl-N2-(4-carboxybenzene-1-sulfonyl)-3-(5-
methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)propan-
amidine (14) Method C. White solid (45 %); m.p. = 234-
237 °C; Rf = 0.37 (CH2Cl2/MeOH 20:1); UV (MeOH): 
λmax /nm: 218 and 247 (log ε /dm3 mol–1 cm–1: 4,6 and 
4,6); 1H NMR (300 MHz, DMSO-d6) δ /ppm: 13.32 
(brs, 1H, COOH), 11.24 (s, 1H, NH-3'), 8.88 (d, 1H, J = 
6.6 Hz, NH- cyclopentyl), 8.08 (d, 2H, J = 8.5 Hz, Ph), 
7.93 (d, 2H, J = 8.5 Hz, Ph), 7.20 (pd, 1H, J = 1.2 Hz, 
H-6'), 4.01 (t, 2H, J3,2 = 6.0 Hz, CH2-3), 4.01 (m, 1H, 
CH- cyclopentyl), 2.93 (t, 2H, J2,3 = 6.1 Hz, CH2-2), 
1.76 (m, 2H, CH2- cyclopentyl), 1.71 (s, 3H, CH3-5'), 
1.58-1.33 (m, 6H, CH2- cyclopentyl); 13C NMR (150 
MHz, DMSO-d6) δ /ppm: 166.35 (s, COOH), 164.57 (s, 
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C-4'), 164.31 (s, C-1), 150.71 (s, C-2'), 147.66 (s, Ph), 
140.97 (d, H-6'), 133.41 (s, Ph) 129.83 (d, Ph), 125.88 
(d, Ph), 108.39 (s, C-5'), 53.06 (d, CH- cyclopentyl) 
45.49 (t, CH2-3), 33.34 (t, CH2-2), 31.35 (t, CH2- 
cyclopentyl), 23.53 (t, CH2- cyclopentyl), 12.00 (q, 
CH3-5'); IR (KBr) ν /cm–1: 3326 (m), 3139 (w), 3045 
(w), 2958 (w), 2869 (w), 2810 (w), 1698 (s), 1678 (s), 
1552 (s), 1284 (m), 1147 (m), 1087 (m). Anal. Calcd. 
mass fractions of elements, w /%, for C20H24N4O6S × 
0,25 H2O (Mr = 453.00): C, 53.03; H, 5.45; N, 12.36; S, 
7.08. Found: C, 53.00; H, 5.63; N, 11.96; S, 7.02. 
 
X-ray Structures 
Crystal data, data collection and refinement parameters 
are summarized in Table 1. Colourless prisms suitable 
for data collection were obtained by slow evaporation of 
a 1:1 mixture of methanol and dichloromethane at 4 °C. 
Data collection was performed on a prism 0.3 × 0.2 × 0.2 
mm, on an Oxford Diffraction Xcalibur Nova R 
diffractometer with a microfocusing Cu tube (λ = 
1.54179 Å). Data reduction and cell refinement were 
carried out using the CRYSALIS PRO software.19 In-
tensities were measured at room temperature since crys-
tals do not show any sign of decay. The structure was 
solved using direct methods with SHELXS8620 and 
refined using full matrix least-squares refinement based 
on F2, with SHELX97.21 Molecular illustrations were 
prepared with ORTEP-3,22 and MERCURY23 included 
into the WinGX package.24 All non-solvent non-
hydrogen atoms were refined anisotropically. A water 
molecules oxygen atom with a population of 0.25 was 
refined isotropically. All hydrogen atoms were included 
in their geometrically calculated positions and refined 
according to the riding model. 
 
Cell culturing and MTT test25 
N-sulfonylamidino thymine derivatives 2 and 6 were 
selected for preliminary in vitro testing on cytotoxicity 
using normal Madine-Darby canine kidney (MDCKI) 
cells, human cervix adenocarcinoma (HeLa), and human 
T-cell leukemia (Jurkat) cell lines. HeLa and MDCKI 
cells were grown in DMEM medium (Gibco, EU) while 
Jurkat cells were grown in RPMI 1640 medium (Gibco, 
EU). Both media were supplemented with 10 % heat-
inactivated fetal bovine serum-FBS (Gibco, EU), 2× 
10–3 M glutamine (Gibco, EU), 1 ×10–3 M sodium py-
ruvate (Gibco, EU), 1×10–2 M HEPES (Sigma-Aldrich, 
USA) and 100 U/0.1 mg antibiotic/antimycotic (Gibco, 
EU). Cells were grown on 37 °C, with 5 % CO2 gas in 
humidified CO2 incubator (ShelLab, Sheldon Mfg. Inc., 
USA). Trypan blue dye exclusion method was used to 
assess cell viability. Tested compounds were dissolved 
in dimethyl sulfoxide as a 1 ×10–2 M stock solution. 
Working dilutions were prepared in high pure water at a 
concentration range 10–3–10–6 mol dm–3. 
For the MTT test, cells were seeded on 96 micro 
well flat bottom plates (Greiner, Austria) at 2 × 104 
cells /mL. After 72 hours of incubation with the tested 
compounds MTT (Merck, Germany) was added. DMSO 
(Merck, Germany) was used to dissolve the formed 
MTT-formazane crystals. Absorbency was measured at 
570 nm on Stat fax 2100 plate reader (Awareness Tech-
nology Inc. USA). All experiments were performed 
three times in triplicates. The IC50 value, defined as the 
concentration of compound (1 × 10–6 M) achieving 50 % 
of cell growth inhibition, was calculated and used to 
compare cytotoxicity among the compounds. 
 
RESULTS AND DISCUSSION 
Synthesis. 
Click chemistry developed by Meldal26 and Sharpless27 
involving the Cu(I)-catalyzed 1,3-dipolar azide alkyne 
cycloaddition into 1,4-disubstituted 1,2,3-triazoles has 
found extensive application in the construction of com-
plex molecules of interest in materials,28 biological29 
and medicinal30 chemistry. The scope and potential of 
Table 1. Crystallographic data 
Structure 1 
Moiety formula C22H31N5O5S, 0.25 (H2O) 
Formula weight / g mol–1 481.59 
Space group C2/c 
a / Å 50.8502 (19) 
b / Å 5.9521 (1) 
c / Å 52.055 (2) 
 /  161.773 (1) 
V / Å3 4928.0 (3) 
 8 
ρcalc / g cm–1 1.298 
μ(CuKα) / mm–1 1.531 
Absorption correction multiscan 
F(000) 2048 
 max /  62.07 
No. refl. measured 14320 
No. refl. unique 3827 
No. refl. observed [I > 2σ(I )] 3318 
Rint 0.0317 
Rσ 0.0194 
Parameters 290 
R1 [I > 2σ(I )] 0.0590 
wR2, all 0.1898 
S 1.056 
ρmax, ρmin / e Å–3 0.60, –0.29 
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the latter reaction have been extended by a recent dis-
covery of Chang and co-workers.31,32 They have found 
that by reacting alkynes with electron deficient azides 
such as acyl, sulfonyl and phosphoryl azides and prima-
ry or secondary amines, amidines are formed in excel-
lent yields under mild reaction conditions. The reaction 
is of wide scope and enables an easy one-pot access  
to amidines, which could be otherwise conventionally 
prepared by functional group transformation from am-
ides, thioamides, nitriles, isonitriles or oximes.33 The 
three component reaction is shown to proceed via the 
ketenimine intermediate, generated in situ by the Cu(I)-
catalyzed coupling of 1-alkynes and sulfonyl azides 
upon the release of N2.34  
The latter reaction has been selected as the most 
promising approach to the series N-sulfonylamidino 
thymine derivatives II (Figure 1), starting from easily 
accessible 1-propargyl thymine as the alkyne compo-
nent, commercial 4-acetamidobenzenesulfonyl, 4-methyl-
benzenesulfonyl and 4-carboxybenzenesulfonyl azides 
and various primary and secondary amines. The starting 
1-propargyl thymine was obtained by a slight modifica-
tion of the Woodman method.35 For this, thymine was 
activated with N,O-bis(trimethylsilyl)acetamide (BSA) 
in acetonitrile and treated with propargyl bromide, giv-
ing exclusively the N-1 alkylated product in 63 % yield. 
Cu(I)-catalyzed three-component coupling reactions of 
1-propargyl thymine with three different commercially 
available benzenesulfonyl azides and primary and sec-
ondary amines were conducted at room temperature in 
THF. In this way, N-alkyl- (3, 4, 5, 9, 13, 14) and N,N-
dialkyl-(1, 2, 8, 12) sulfonylamidine derivatives were 
prepared in the 43–78 % yields (Table 2). In the cou-
plings, 20 % molar excess of the sulfonyl azide and 
amine component was used. In the reactions with  
4-carboxybenzenesulfonyl azide possessing a free car-
boxylic group addition of 140 % molar excess of amine 
was used. Benzenesulfonyl amidine products 12, 13  
and 14 possessing a free carboxylic group at para posi-
tion were obtained in 43–45 % yield. Reactions of  
1-propargyl thymine and 4-acetamidobenzenesulfonyl 
azide or 4-methylbenzenesulfonyl azide (tosyl azide) 
with secondary amines (Table 2, 1, 2 and 8) gave 
somewhat better yields compared to those with pri-
mary amines (Table 2, 3, 4 and 9) and aromatic amine 
(Table 2, 5), presumably due to higher nucleophilicity 
of the former.34b 
In all reactions with 4-acetamidobenzenesulfonyl 
azide, the presence of a small amount of 4-acetamido-
benzenesulfonyl amide by-product was observed. It is 
reported in the literature that sulfonamide may be 
formed from the corresponding sulfonyl azide by its 
decomposition or during the transfer of diazo group to 
carbon or nitrogen; it can be also obtained from the 
azide under reductive conditions in the presence of 
copper powder in aqueous media.36–38 
We have found that the amount of 4-acetamido-
benzenesulfonyl amide by-product increases with in-
creasing reaction temperature, which indicates that its 
formation could be mostly a consequence of thermal 
decomposition of the starting azide.  
Ammonium salts were found to be a convenient 
substitute for the amine component in the Cu-catalyzed 
Table 2. Three-component coupling reactions of 1-propargyl 
thymine with various aromatic sulfonyl azides, amines and 
ammonium salts. 
 
Product Azide Amine Yield / %(a)
1 
 
78(b) 
2  
 
64(b) 
3   54
(b) 
4   58
(b) 
5   54
(b) 
6   45
(c) 
7   56
(c) 
8 
  
54(b) 
9   45
(b) 
10   30
(c) 
11   39
(c) 
12 
  
43(d) 
13   43
(d) 
14   45
(d) 
(a) Yields of analytically pure products. 
(b) Method A: alkyne (1 mmol), sulfonyl azide (1.2 mmol), amine 
(1.2 mmol), CuI (0.1 mmol) in THF (2.0 mL) at 25 °C for 24 h.
(c) Method B: alkyne (1 mmol), sulfonyl azide (1 mmol), amine/ 
ammonium salt (1 mmol), CuI (0.1 mmol) triethylamine (1.5 
mmol) in CH2Cl2 (2–5 mL) at 25 °C for 24 h. 
(d) Method C: alkyne (1 mmol), sulfonyl azide (1.2 mmol), amine 
(2.4 mmol), CuI (0.1 mmol) in THF (2.0 mL) at 25 °C for 24 h.
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three-component reactions.39 Using ammonium chloride 
and 4-(aminomethyl)benzonitrile hydrochloride N-un-
alkylated (7, 11) and N-monobenzylated (6, 10) 
sulfonylamidines, respectively, were prepared (Table 2). 
The reactions were performed in dichloromethane at 
room temperature in the presence of excess triethyla-
mine. Although it has been reported39 that the use of 
ammonium hydroxide instead of ammonium chloride 
gave better yields of respective amidines, this was not 
the case in our reaction examples. By using ammonium 
hydroxide, the expected N-unalkylated sulfonylamidine 
7 formed only in 30 % yield after heating the reaction 
mixture to 50 °C. The attempted preparation of N-un-
alkylated sulfonylamidine in the reaction with 4-carb-
oxybenzenesulfonyl azide and ammonium chloride was 
unsuccessful even in refluxing dichloromethane. 
 
Molecular and Crystal Structure. 
Compound 1 crystallizes in the monoclinic 
centrosymmetric space group C2/c with one molecule in 
the asymmetric unit and a water molecule with the oc-
cupancy factor of 0.25. The X-ray structure discloses 
the E-form of the generated amidine C10=N9 double 
bond (torsion angle C18-C10-N9-S1, 2.9(3)°, see Figure 
2). Bond lengths N9–C10 and C10–N11 of the amidine 
group (see Table 3) are compared with analogous bond 
lengths of the set of 78 related structures (138 structural 
fragments) extracted from the current version of the 
Cambridge Structural Database.40 The R-N=C(R)-N(R2) 
fragment was given as input, where R stands for any 
non-hydrogen atom. Structures with R factor exceeding 
5 %, as well as metal or ion containing structures were 
excluded. The average value of the N=C bond length 
(analogue of N9=C10 in 1) is 1.307 (2) Å, while 
1.364(2) Å is the average value of the N-C bond (ana-
logue of N11-C10 in 1). Comparison of these values 
with the corresponding values for N9=C10 and C10-
N11, listed in Table 3, strongly suggests that in the case 
of 1, the double bond character in the generated amidine 
is delocalized over two C–N bonds. Terminal acetamido 
moiety reveals a strong static disorder, resulting in unu-
sually large displacement parameters of C1, C2, and O1 
atoms, as well as somewhat unreliable geometry in this 
part of the molecule (See Figure 2). During refinement, 
the phenyl ring C3-C4-C5-C6-C7-C8 was constrained to 
the idealized six-membered ring geometry. Neverthe-
less, all non-solvent non-hydrogen atoms were refined 
anisotropically. Thymine rings in both molecules have 
the usual and expected geometries. 
Crystal packing of 1 is guided by the centrosym-
metrical hydrogen-bonded dimers formed via two 
neighboring thymine moieties. They use their N22 and 
O5 atoms as proton donors and acceptors, respectively. 
Two hydrogen bonds, N22-H22···O5i (1-x,2-y,1-z) and 
its centrosymmetric counterpart form an H-bonded ring 
of the graph-set notation 22R  (8).
41 These dimers are 
further interconnected via water bridges, where O6 
plays the role of a pillar in the hydrogen bonded bridge 
between N3 and O1 from the neighboring dimer. In this 
way, a dimer of dimers is formed as a distinct building 
element of the crystal packing of 1 (Figure 3). 
 
In vitro Cytotoxicity Screening 
N-sulfonylamidino thymine derivatives 2 and 6 were 
selected for preliminary in vitro cytotoxicity testing 
against normal Madine Darby canine kidney (MDCKI) 
cells, and two tumor cell lines of different histological 
origin, human cervix adenocarcinoma (HeLa) and T cell 
leukemia cells (Jurkat).25 As shown in Figure 4. both 
compounds have a similar pattern of cytotoxic capacity. 
Their inhibition potential differs in dependence on the 
dose applied as well as on the cell line treated. Com-
pound 2 showed 60 % growth inhibition of HeLa cells 
applied at 10–5 and 10–6 M concentrations and 50 % 
inhibition of Jurkat cells at the 10–5 M concentration. 
Compound 6 inhibited the growth of HeLa cells by 60 % 
Figure 2. ORTEP drawing of compound 1 with atom number-
ing. Displacement parameters are scaled to 50 % probability
value. 
Table 3. Selected bond lengths in the structure of 1. 
Bond Distance / Å 
S1–C6 1.750 (2) 
S1–O2 1.427 (3) 
S1–O3 1.439 (2) 
S1–N9 1.610 (2) 
N9–C10 1.316 (3) 
C10–N11 1.335 (3) 
N20–C21 1.362 (3) 
C21–N22 1.370 (3) 
N22–C23 1.382 (3) 
C23–C24 1.447 (4) 
C24–C25 1.338 (4) 
C25–N20 1.384 (3) 
C19–N20 1.461 (3) 
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at 10–5 and 10–6 M concentrations. In comparison with 
HeLa cells, Jurkat cells were less sensitive to the 10–5 M 
compound 6 and inhibition was near 40 %. The growth 
inhibitory effects on normal MDCKI cells were much 
smaller (Figure 4). Detailed cytotoxicity in vitro screen-
ing of the complete series of compounds is under way. 
 
CONCLUSION 
We report an efficient one-pot synthesis of a small li-
brary of novel N-sulfonylamidino thymine derivatives 
by Cu(I) catalyzed three component reaction of 1-pro-
pargyl thymine, selected benzenesulfonyl azides and 
primary amines, secondary amines and ammonium salts. 
The prepared compounds represent a combination of 
three important pharmacophores, thymine nucleobase, 
N-sufonyl group and amidine group. We show that this 
one-pot three component reaction appears to be favour-
able for the preparation of variously substituted N-sulfo-
nylamidino thymine derivatives in moderate to good 
yields and opens the way for preparation of libraries of 
other nucleobase N-sulfonylamidino derivatives as po-
tential biologically active molecules. Preliminary anti-
cancer in vitro screening against human solid tumor 
(HeLa) and leukemia (Jurkat) cells showed that some of 
the prepared N-sulfonylamidino thymine derivatives of 
type II possess promising anticancer activity. Extensive 
studies on further evaluation of the biological potential 
of these new structures are under way.  
Supplementary Materials. – CCDC 900214 contains the supple-
mentary crystallographic data. These data can be obtained free 
of charge via http://www.ccdc.cam.ac.uk/conts/retrieving.html,  
or from the Cambridge Crystallographic Data Centre, 12 Union 
Road, Cambridge CB2 1EZ, UK; fax: (+44) 1223-336-033; or 
e-mail: deposit@ccdc.cam.ac.uk.  
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